TONVASCA Effective Lipid Reduction, Easy Goal Achievement

12-week treatment effectively reduces LDL-C by over 50%, helping nearly 95% of diabetic patients reach their LDL-C target.

2023 ADA Guidelines for LDL-C Targets in High-Risk Patients

LDL-C Target Values	
Primary Prevention	
(Ages 40-75, No ASCVD but with Risk Factors)	**LDL-C <70 mg/dL and ≥50% Reduction**
Secondary Prevention	
(Diabetic Patients with ASCVD)	**LDL-C <55 mg/dL and ≥50% Reduction**

High-Risk Patients with Diabetes Using TONVASCA Effectively Achieve LDL-C Target in 12 Weeks+





Target defined as LDL-C < 100 mg/dL

Study Design

Multinational, multicenter, randomized controlled clinical trial

Study Population

Patients aged 20–80 years with primary hypercholesterolemia or mixed dyslipidemia

testing drug

TONVASCA (pitavastatin/ezetimibe 2/10 mg) (N=122)
Pitavastatin 2 mg (N=126)
Ezetimibe 10 mg (N=124)

ADA, American Diabetes Association; ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.

References: 1. Chou MT, et al. Clin Ther. 2022;S0149-2918(22)00286-7. 2. ElSayed NA, et al., Diabetes Care 2023;46(Suppl. 1):S1–S4.

For Medical Professionals Only

TONVASCA Patented Dual Microgranule Encapsulation Design

Special microgranule formulation enhances product stability and ease of use.
Patented by the Taiwan Intellectual Property Office.



- **Flexible Administration:** Capsules can be taken whole or opened and sprinkled in water.
- **Enhanced Stability:** Reduces drug degradation, ensuring 100% bioavailability.

Exclusive Benefits

- Patented dual microgranule technology optimizes drug absorption.
- TONVASCA minimizes drug interactions, improving treatment effectiveness

References: 1. Data on file. 2. TONVASCA 鼻胃管試驗報告。3. 中華民國專利證書號數：I760067 / 專利公報。

orientPHARMA 友霖生技

TONVASCA capsules 2/10mg